<DOC>
	<DOC>NCT01849497</DOC>
	<brief_summary>The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in home-use using either a pre-filled syringe or autoinjector/pen.</brief_summary>
	<brief_title>Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Fasting LDLC at screening &gt; 85 mg/dL Fasting triglycerides less than or equal to 400 mg/dL (4.5 mmol/L) Exclusion Criteria: New York Heart Association (NYHA) III or IV heart failure Uncontrolled cardiac arrhythmia Uncontrolled hypertension Type 1 diabetes or poorly controlled type 2 diabetes Uncontrolled hypothyroidism or hyperthyroidism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>LDL-C, triglycerides, high cholesterol</keyword>
</DOC>